Trial Profile
Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Oct 2013
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Fracture; Osteoporosis
- Focus Therapeutic Use
- 17 Oct 2013 New trial record
- 01 Apr 2013 Preliminary results published in the Journal of Arthroplasty.